J Clin Endocrinol Metab 96:853860 Mabilleau G, Mieczkowska A, Irwin N, Flatt PR, Chappard D (2013) Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor
[5961] With increasing attention on the metabolic role of MSTN, a study demonstrated that inhibition of MSTN ameliorated type 1 diabetes in mice by improving insulin sensitivity and enhancing the expression of Glut1 and Glut4 glucose transporters in skeletal muscle.[62] This was found to be the same in humans as elevated circulating MSTN levels have also been found in patients with type 1 diabetes.[63] Collectively, these observations highlight the therapeutic potential of targeting MSTN for the treatment of metabolic disorders, including obesity and diabetes
Similar guidance would likely apply to retatrutide, but this has not been formally established
As an investigational peptide not yet FDA-approved, retatrutide is available through research chemical suppliers and certain compounding pharmacies
Low JK, Crawford K, Manias E, Williams A
Significantly so